Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Soraprazan vs esomeprazole in non-erosive gastroesophageal reflux disease (NERD)
2006-002779-42Phase 2Terminated
- Sponsor
- Altana Pharma
- Start
- Aug 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of soraprazan in gastroesophageal reflux disease (GERD) (3 arms), sponsored by Altana Pharma. Primary endpoint: Symptom relief over first 3 days (ReQuest-GI). Started Aug 2006; status: terminated.
02
Drugs
soraprazan
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on 2006-002779-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002779-42.